tiprankstipranks
Trending News
More News >

Noxopharm Advances HERACLES Clinical Trial for Autoimmune Drug

Story Highlights
Noxopharm Advances HERACLES Clinical Trial for Autoimmune Drug

Don’t Miss TipRanks’ Half-Year Sale

Noxopharm Ltd. ( (AU:NOX) ) has issued an announcement.

Noxopharm Limited has announced significant progress in the recruitment phase of its HERACLES clinical trial, which is testing SOF-SKN™, a first-in-class drug candidate for autoimmune diseases. The trial aims to assess the safety of SOF-SKN in treating cutaneous lupus erythematosus and potentially other autoimmune-related skin conditions. The company has completed the manufacturing of SOF-SKN and is finalizing quality control measures, with the trial benefiting from Australian expertise and federal R&D tax incentives. This advancement underscores Noxopharm’s strategic focus on leveraging its Sofra™ technology for broader applications in autoimmune and inflammatory diseases.

More about Noxopharm Ltd.

Noxopharm Limited is a clinical-stage Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages its proprietary technology platforms, Sofra™ and Chroma™, to enhance mRNA medicines and develop drugs targeting inflammation, autoimmunity, and oncology.

Average Trading Volume: 105,819

Technical Sentiment Signal: Sell

Current Market Cap: A$17.53M

For a thorough assessment of NOX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1